Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INT301 in adults with peanut allergy
NCT04603300Phase 1Completed
- Sponsor
- Intrommune Therapeutics
- Start
- May 2021
- Primary completion
- Jun 2023
- Modality
- Prophylactic Vaccines, Allergy Immunotherapy
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of INT301 in peanut allergy (2 arms), sponsored by Intrommune Therapeutics. Primary endpoint: Safety of INT301 compared to placebo at 48 weeks. Started May 2021; status: completed.
02
Drugs
INT301
03
Conditions
peanut allergy
Beyond the preview
Go deeper on NCT04603300.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04603300.